U lcerative colitis (UC) is a chronic relapsing-remitting inflammatory disease of the colon. Approximately 25% of patients with UC will develop a severe acute attack during their life leading to hospital admission. 1 Corticosteroids remain the treatment of choice for moderate and severe UC attacks, but 30% to 50% of patients fail to respond and require rescue therapies. [2] [3] [4] Great efforts have been made to identify predictors of response to corticosteroids in the treatment of acute UC flares, so as to avoid their deleterious effects, delay in disease control, and worsening of patient well-being. Stool frequency, rectal bleeding, and C-reactive protein (CRP) levels as measured between days 3 and 5 after starting intravenous corticosteroids have been repeatedly correlated with risk of colectomy and lack of clinical response to corticosteroids, [4] [5] [6] and have been widely implemented as predictors in clinical practice, allowing an earlier introduction of rescue therapies. Cyclosporine A (CsA) became the first alternative to colectomy for steroid-refractory ulcerative colitis (SRUC) attacks in the mid-1990s. 7 This calcineurin inhibitor demonstrated short-term efficacy in SRUC attacks, with up to 85% of patients achieving clinical response. 8 Once remission has been achieved, long-term maintenance treatment with thiopurines is generally advised, 9 but the long-term outcome of these patients is still controversial. [10] [11] [12] [13] Almost 1 decade later, infliximab (IFX), a chimeric humanmurine monoclonal antibody that binds to tumor necrosis factor alpha, was introduced as an effective therapy for UC, 14 even in SRUC episodes. 15 In patients responding to IFX, long-term maintenance therapy may include infliximab monotherapy, thiopurine monotherapy (after completing at least 1 induction scheme), or a combination of both. However, data on the longterm efficacy of IFX in preventing colectomy after SRUC episodes are still scarce. Since the advent of IFX, whether CsA or IFX should be the drug of choice in SRUC has been a matter of debate. A recent RCT comparing both drugs showed similar efficacy in inducing clinical remission and preventing colectomy in the short term. 16 Beyond short-term efficacy of both drugs, some other factors may aid decision making in the setting of SRUC attacks. Some retrospective studies have reported that, when a first-line rescue therapy fails, salvage treatment with a second drug avoids colectomy in almost half of patients, suggesting that sequential therapy might be considered at least in selected patients. [17] [18] [19] [20] Most available data provide the outcome of patients in whom CsA was the first rescue therapy, probably because of the hypothetical higher risk of profound immunosuppression due to pharmacokinetic reasons if IFX is used first. Additionally, long-term maintenance therapy should also be taken into account in decision making. Although thiopurines are the only accepted long-term maintenance therapy after initial success of CsA, patients responding to treatment of SRUC with IFX can be maintained with combination therapy (IFX plus thiopurines), IFX monotherapy, or even thiopurine monotherapy.
Under this perspective, the management of SRUC should focus not only on the choice between CsA and IFX, but also on long-term maintenance therapy and on the possibility of the second salvage therapy to avoid colectomy. Thus, the aim of our study was to compare the long-term outcome of 2 different treatment strategies according to the first rescue therapy used in patients with SRUC.
PATIENTS AND METHODS
Between January 2005 and December 2011, all patients admitted for UC attacks requiring rescue therapy due to lack of response to intravenous corticosteroids were identified from the electronic records of 3 referral university hospitals. Patients were grouped according to whether they received CsA or IFX as firstline rescue treatment. Patients receiving CsA were treated intravenously with a dose of 2 to 4 mg/kg per day. Serum trough levels were measured every 48 to 72 hours, and the dose was adjusted to achieve nontoxic drug levels. Patients achieving clinical remission were thereafter maintained with oral azathioprine (AZA), 2.5 mg/kg per day, without oral CsA bridging as previously described by our group. 9 Patients receiving IFX were treated with a 5-mg/kg infusion at weeks 0, 2, and 6 and concomitant thiopurines (if tolerated), and, in case of clinical response, maintenance treatment with AZA, IFX (5 mg/kg every 8 wk), or both were prescribed at the discretion of the treating physician. Corticosteroids were tapered at discharge, and the dose was reduced by 10 mg weekly until reaching 20 mg and by 5 mg weekly thereafter until complete withdrawal.
Relevant information regarding epidemiological, clinical, biological, and treatment variables was collected. For the purposes of this study, we arbitrarily defined initial efficacy as steroid-free clinical remission (by means of an inactive or mild Montreal severity score 21 ), with no need for the second rescue treatment or early colectomy. Switch was defined as the need for the second rescue drug after a first-line rescue treatment failure during the steroid tapering period. Early colectomy was defined as the need for surgery during hospital admission or during the steroid tapering period. Late colectomy was defined as the need for surgery during follow-up and after achieving steroid-free clinical remission. Patients were followed until colectomy, death, or the end of data collection (October 2013).
This study was approved by the institutional review board of the coordinating center (Hospital Universitari Germans Trias i Pujol). All statistical analyses were carried out in SPSS12.0 for Windows (SPSS Inc., Chicago, IL). Data are expressed as median and interquartile range (IQR) or absolute and relative frequencies. Chi-square analysis and Student's t test were performed for between-group comparison of qualitative and quantitative variables, respectively. Variables reaching a P-value #0.2 on univariate analysis were included in the Cox regression analysis to identify predictors of initial efficacy or colectomy. The cumulative probability of colectomy was calculated by the Kaplan-Meier method.
RESULTS
Fifty patients with a SRUC episode were included. Twenty patients received CsA as first-line rescue therapy (CsA-based strategy), and the remaining 30 patients received IFX (IFX-based strategy). Of note, more than two-thirds of patients had extensive UC, 80% were former or never smokers, 20% of episodes occurred at UC onset, and 26% had previous exposure to thiopurines. As shown in Table 1 , no differences regarding epidemiological and clinical features or laboratory parameters were found between the 2 groups, except for a significantly shorter median time from intravenous corticosteroid initiation to rescue therapy (7 d [IQR, (4) (5) (6) (7) (8) (9) versus 10 days [IQR, 7-13], P ¼ 0.027) and a higher proportion of patients with severe activity immediately before rescue therapy (50% versus 20%, P ¼ 0.026) in the CsA-based group as compared with the IFX-based group. In 2005 and 2006, there was a predominance of the CsA-based strategy, whereas the IFXbased strategy was predominant thereafter (Fig. 1) . The median follow-up was 44 months (IQR, 14-68) in the CsA-based group and 36 months (IQR, 27-49) in the IFX-based group.
Initial Efficacy
Thirty-nine patients (78%) achieved steroid-free clinical remission with no need for the second rescue treatment or early colectomy (Fig. 2) . In the IFX-based group, 4 out of 30 (13%) did not fulfill initial efficacy criteria, one of whom was earlycolectomized, 2 patients avoided early colectomy through CsA as second-line rescue therapy (one was lately colectomized), and the remaining patient avoided early colectomy by treating colonic cytomegalovirus reactivation but was also lately colectomized during follow-up after a failed attempt at CsA treatment. In the CsA-based group, 7 out of 20 (35%) did not achieve initial efficacy, of whom 6 were switched to IFX (avoiding early colectomy in 5 cases), and the remaining patient was earlycolectomized. Although there was a clear trend toward greater initial efficacy in the IFX-based group, it did not reach statistical significance (P ¼ 0.07). In fact, lower CRP level at day 3 after starting intravenous corticosteroids was the only independent predictor of initial efficacy on multivariate analysis (P ¼ 0.03) ( Table 2) . Moreover, a higher number of patients in the CsAbased group were switched to a second-line treatment when compared with the IFX-based group (30% versus 7%, P ¼ 0.04). Interestingly, half of the patients who were switched (3 in the CsA-based group and 1 in the IFX-based group) avoided colectomy over the study period.
As shown in Figure 2 , 8 patients were early switched to the second salvage therapy (6 IFX after CsA and 2 CsA after IFX). Only 1 severe infection was noticed among these patients. He was a patient who was initially treated with CsA and early switched to IFX because of lack of response. A few days after the first IFX infusion, the patient presented fever and was diagnosed with Listeria monocytogenes septicemia. A good clinical response was achieved with ampicillin and gentamicin for 2 weeks, and IFX therapy was restarted once the infection was cured. No deaths were noticed among these 8 patients at the end of the study.
Follow-up After Corticosteroid Withdrawal
Forty-seven patients avoided early colectomy because of initial efficacy or switch to a second-line drug therapy. The longterm outcome of these patients is summarized in Figure 3 . In all, 35 patients (70% of the whole series) remained free of colectomy after a median follow-up of 37 months (IQR, 25-52).
In the CsA-based group, most patients received maintenance therapy with thiopurines (13 out of 18), although in 1 patient, azathioprine had to be discontinued because of hepatotoxicity and thrombocytopenia. The remaining 5 patients received combination therapy with IFX and thiopurines. After a median follow-up of 48 months (IQR, 22-72), IFX was required in 5 patients. Four patients were colectomized during follow-up, all of whom had received IFX (early or late after SRUC episode) before colectomy (Fig. 3) .
Patients in the IFX-based group who avoided early colectomy were maintained with combination therapy (47%), thiopurines (37%), or IFX monotherapy (13%). One patient on combination therapy had to discontinue IFX because of a severe acute infusion reaction. After a median follow-up of 36 months (IQR, 28-49), 2 patients needed rescue therapy with CsA, and 8 patients were colectomized (including the 2 who required CsA). Of note, 6 of the 8 colectomies were performed within the first year after the index flare. The cumulative probability of colectomy was 14%, 16%, and 21% at 1, 2, and 3 years, respectively. Colectomy rates were identical for both therapeutic strategies at the end of follow-up (30%) (Fig. 4) . Previous thiopurine exposure (P ¼ 0.004; odds ratio ¼ 6.1 [1.7-20.9]) was the only predictor of colectomy on Cox regression analysis (Table 3 ). There were no deaths during admission or follow-up. One patient in the IFX-based group developed colorectal cancer. 
DISCUSSION
This study was focused on the comparative evaluation of short-term and long-term outcomes between 2 different strategies for the management of SRUC attacks. We decided to assess steroid-free clinical remission with no need for therapy switching as a measure of the short-term efficacy of the 2 tested drugs.
Although there was a nonsignificant but clear trend in favor of the IFX-based strategy, one must take into account that the CsAbased group had a higher proportion of patients with severe disease activity before the initiation of rescue therapy. In fact, multivariate analysis showed that lower CRP levels were the only predictor of initial efficacy. The most robust data evaluating the short-term efficacy of both drugs for SRUC episodes come from a randomized, open-label, multicenter European study that included 115 patients with SRUC attacks who were randomly assigned to receive 2 mg/kg per day of intravenous CsA for 1 week followed by oral CsA until day 98, or IFX 5 mg/kg at weeks 0, 2, and 6. All patients who achieved clinical response at day 7 received treatment with azathioprine (2-2.5 mg/kg per day). Treatment failure was defined as the absence of response at day 7, relapse between days 7 and 98, absence of steroid-free remission at day 98, severe adverse event that led to treatment discontinuation, colectomy, or death during the study period. No efficacy or safety differences were found between the 2 treatments during the study period. 16 In addition, several retrospective series from clinical practice show controversial results, probably due to marked differences in treatment schedules. Sjöberg et al reported a significantly higher colectomy rate at 3 and 12 months in patients treated with IFX. Although 80% of patients in both groups received maintenance treatment with immunomodulators, patients in the IFX group received only a single dose of the drug for induction of remission. 22 By contrast, Croft et al, in a similar study, reported significantly lower rates of colectomy in the short and long term among IFX-treated patients as compared with CsA-treated patients for SRUC attacks. 23 Dean et al, in a smaller series, also reported greater benefits from IFX therapy (1-5 infusions), although CsA-treated patients were older and had higher CRP levels. 24 Even less is known about differences in long-term outcomes between these 2 rescue drugs. The only available data come from a retrospective study published by Mocciaro et al that included 65 SRUC patients (35 rescued with CsA and 30 rescued with IFX). No differences in colectomy rate were found between the 2 drugs at 3 months, but significant long-term benefits were observed with IFX. 25 However, it is important to note that about half of the patients treated with CsA did not receive thiopurines because of previous intolerance, a fact that surely influenced the long-term results as far as maintenance treatment with thiopurines was found to decrease the risk of colectomy.
However, none of the above-mentioned studies took into account the possibility of switching rescue therapies before colectomy, a strategy that is frequently used in clinical practice. Our data show that half of the patients who were switched early to IFX or CsA avoided colectomy, in agreement with several retrospective series. [18] [19] [20] In our series, 30% of patients initially treated with CsA were rescued early with IFX, with 80% avoiding early colectomy. Moreover, we showed that up to 30% of patients achieving steroid-free clinical remission with CsA required IFX later during the follow-up period.
Given the similar short-term efficacy of both drugs, many other factors can influence decision making when facing a SRUC episode. Safety profile and contraindications, previous intolerance to thiopurines, economic considerations (healthcare reimbursement), or even long-term patient convenience (regarding oral or intravenous maintenance therapy) may play a role. However, good predictors of response should ideally be the main arguments for choosing one drug in favor of another in a particular patient. Our study suggests that patients with more severely active disease at the time of first rescue therapy have a poorer prognosis in both the short and the long term. Initial efficacy was associated with lower CRP levels at day 3 of intravenous corticosteroids; similarly, severe activity immediately before rescue therapy was significantly associated with colectomy on univariate analysis and showed a marked trend (P ¼ 0.006) on multivariate analysis. Mocciaro et al also found that higher CRP levels, as well as extensive disease, were associated with an increased risk probability of colectomy. 25 Disease severity as measured by several clinical indexes at the time of rescue therapy onset was shown to increase the risk of colectomy in large series treated with CsA for SRUC 26, 27 and in the first RCT evaluating IFX for SRUC. 15 In addition, we also found that previous exposure to thiopurines was clearly associated with an increased risk of colectomy. Our findings are in agreement with previous studies in which previous exposure to azathioprine was independently associated with increased risk of colectomy 22 or poorer response to CsA. 13, 23 The major drawbacks of this study are its retrospective design and small sample size. Nevertheless, our assessment of treatment strategies instead of drug efficacy alone explored what is relevant in daily clinical practice. Moreover, the long-term follow-up provides important data regarding the need for other courses of rescue therapies once clinical remission of a first SRUC episode has been achieved.
In summary, this study did not find marked differences in the long-term outcome of SRUC attacks depending on the drug initially chosen to induce clinical remission. However, taking into account that patients previously exposed to thiopurines are at higher risk of colectomy and that thiopurines or IFX are the only maintenance therapies available to maintain drug-induced clinical remission, IFX should be the first choice in this subset of patients. Sequential therapy with CsA and IFX in selected patients may reduce colectomy rates; thus, CsA might be the first-line therapy of choice in thiopurine-naive patients experiencing nonsevere SRUC episodes. Given that patients with severe UC activity are less likely to respond to either therapy and that switch from one drug to another is less likely in this clinical setting because of the risk of severe infections, the drug of choice in thiopurine-naive patients with severe inflammatory activity remains to be established.
